

August 24, 2011

To Whom It May Concern:

Yoshiji KIMURA
Representative Director of the Board and
Chief Executive Officer
MEDINET Co., Ltd.
(TSE-Mothers #2370)
2-5-14, Shin-Yokohama, Kohoku-ku,
Yokohama, Kanagawa, Japan
Tel: +81 (0)45-478-0041 (Switch Board)
Email: ir@medinet-inc.co.jp

The European Patent Office Granted HSP105

[Translation for Information Purposes Only]

MEDINET Co., Ltd. ("MEDINET") announced that the European Patent Office has granted the right of HSP105 by European Patent Application (No.03791418.1) in the 11 designated countries on August 24, 2011.

The present invention relates to a novel human cancer antigen peptide that is useful for prevention and/or therapeutic treatment of various types of cancers such as pancreatic cancer or colon cancer. Since 2008, MEDINET has been carrying out collaborate researches with National Cancer Center in Japan for validating the effectiveness of HSP105 and developing new technologies of antigen-specific CTL response.

MEDINET believes that this grant from the European Patent Office will establish a toehold in a new market for MEDINET. Therefore, MEDINET will work further on development of the HSP105, and will provide further insights into commercialization of HSP105 such as development to cancer vaccines, application to Dendritic Cell (DC) therapy, and licensing-out in the designated countries.

Patent Details

- | | |
|---------------------------------------|--|
| (1) Application Number: | No.03791418.1 |
| (2) Registered Number: | EP1536006 |
| (3) International Application Number: | PCT/JP2003/011049 |
| (4) Date of Filing: | August 29, 2003 |
| (5) Title: | Cancer antigen and use thereof |
| (6) Applicant: | MEDINET Co., Ltd. |
| (7) Designated states: | Germany, France, United Kingdom, Spain,
Italy, Switzerland, Liechtenstein, Belgium,
Netherlands, Sweden, and Denmark |